|
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory diseases. The company focuses on organ-restricted small molecule inhibitors of ALK5 (TGFβR1) to treat conditions with high unmet medical need. Its lead product candidate, ontunisertib (AGMB-129), is an oral gastrointestinal-restricted inhibitor in development for Fibrostenosing Crohn’s Disease. The second clinical-stage candidate, AGMB-447, is an inhaled lung-restricted inhibitor in development for Idiopathic Pulmonary Fibrosis. The company operates through subsidiaries Agomab Spain, S.L.U. and Agomab US, Inc., with research facilities in Spain and the United States. AgomAb Therapeutics NV was incorporated in 2017. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage ir.agomab.com |
| Sector Healthcare | IR page ir.agomab.com | |
|
Tags
fibro-inflammatory diseases, alk5 inhibitors, crohn's disease, idiopathic pulmonary fibrosis, small molecules, clinical-stage, organ-restricted therapy, ontunisertib, AGMB-129, AGMB-447, Agomab Spain S.L.U., Agomab US Inc., STENOVA, NOV-ERA
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 222K |
| P/E | -0.06 |
| P/BV | 0.00 |
| P/S | — |
| P/OCF | 0.00 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -47.8% |
| ROI | -137.5% |
| ROIC | -97.7% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | — |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | — |
| Diluting (TTM) | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 38 |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 |
|---|---|
| Assets | 153.706M |
| Net profit | -62.547M |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.